Division of Medicine, Imperial College School
of Medicine, London W12 0NN, United Kingdom
Received 19 December 2000/Returned for modification 19 February
2001/Accepted 27 June 2001
 |
INTRODUCTION |
The products of phosphoinositide
3-kinase (PI3K) activity play an important role in the regulation of
many cellular functions, including proliferation, viability, motility,
and vesicle transport (24). The PI3K molecules responsible
for their production form a large enzyme family whose catalytic
activity in vitro and sequence alignment form the basis of their
division into three classes (14). Class I PI3K enzymes are
recognized as mediators of receptor signaling, and their role in
intracellular signal transduction has been examined extensively
(15). The class III PI3Ks, such as Vps34p, regulate
vesicle traffic, most likely in a ligand-independent manner
(45). In contrast, little is known about the cellular role
of the class II PI3K enzymes. These enzymes have a higher molecular
mass than either the class I or class III PI3K enzymes, and they are
distinguished by the presence of a PX and C2 domain at their C termini.
Recent studies have revealed that like the class I enzymes, class II
PI3Ks also act downstream of receptors for growth factors
(5), for chemokines (44), and for integrins (49). In addition to the p85-p110
heterodimer, two
class II PI3K enzymes, PI3K-C2
and PI3K-C2
, are recruited to a
phosphotyrosine containing signaling complex following stimulation of
the epidermal growth factor (EGF) receptor (EGFR) (2).
The EGFR (ErbB-1) is one member of the ErbB kinase family that
includes ErbB-2 (p185erbB2/neu), ErbB-3
(p180erbB3), and ErbB-4
(p180erbB4) (30, 40). When EGF binds
EGFR, this interaction promotes receptor subunit homo- and
heterodimerization. In turn, receptor dimerization activates intrinsic
tyrosine kinase activity to create a series of phosphotyrosine docking
sites for signaling molecules that include Grb2, Shc, Src, and
phospholipase C
(11). Although PI3K activity copurifies
with the EGFR, this receptor does not directly bind the class I PI3K
adaptor p85 (9, 37). Instead, the p85-p110
complex
binds ErbB-3, which heterodimerizes with the activated EGFR
(35). Furthermore, p85 may also be recruited to EGFR via
the Grb2-associated binder Gab-1 (41, 48). Recruitment of
the class II PI3K enzyme PI3K-C2
is dependent upon three
phosphotyrosine residues on the activated EGFR; Y992, Y1068, and Y1173
(2). However, it is unclear if PI3K-C2
interacts
directly with the EGFR or if its association is dependent upon an as
yet unidentified intermediary signaling molecule.
Characterization of PI3K-C2
has established that its N-terminal
residues 1 to 331 are sufficient for its interaction with the activated
EGFR. This sequence lacks phosphotyrosine binding motifs; instead it
has three proline-rich regions that have the potential to bind SH3
containing adaptor molecules (20, 39). The adaptor Grb2
consists of a single, phosphotyrosine binding SH2 domain flanked by two
polyproline binding SH3 domains (25). Recruitment of Grb2
to the EGFR following ligand addition has been described extensively,
and its interaction is dependent upon phosphotyrosine residues Y1068
and Y1173 (4, 42). In addition, Grb2 can be recruited to
the EGFR indirectly through its association with the adaptor protein
Shc. Grb2 is recognized for its association with the guanine nucleotide
exchange factor SOS and the sequential activation of the ras GTPase.
However, the Grb2 adaptor also interacts with and may serve to
translocate other signaling molecules that contain proline-rich motifs,
including Gab-1. In this study we examine the role of proline-rich
regions in the recruitment of PI3K-C2
to the activated EGFR and the
contribution made by Grb2.
 |
MATERIALS AND METHODS |
Cell culture.
Stock cultures of mammalian cells were
passaged every 3 to 4 days in 90-mm-diameter dishes (Nunc) using
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 U of penicillin/ml, and 100 µg of
streptomycin/ml (Life Technologies). Cultures were incubated in a
humidified atmosphere of 10% CO2-90% air at
37°C. For experimental use, cells were switched either to DMEM
containing ITS supplement (Sigma) or to 0.2% FBS. After 16 to 48 h, cultures were confluent and quiescent.
Transient expression in mammalian cells.
HEK293 cells were
grown to 50 to 60% confluence and transfected with cDNA constructs
encoding 5' EE epitope-tagged PI3K-C2
in pcDNA 3.0 (Invitrogen)
using calcium phosphate. Cells were harvested 48 h
posttransfection, and protein was isolated following cell lysis at
4°C using 1 ml of lysis buffer (10 mM Tris-HCl [pH 7.6], 5 mM EDTA,
50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 100 µM
Na3VO4, 1% Triton X-100,
and 1 mM phenylmethylsulfonyl fluoride).
Generation of recombinant protein.
cDNA representing the N
terminus of PI3K-C2
(residues 2 to 130, 2 to 143, 2 to 157, 2 to
255, and 2 to 298) was produced by PCR using oligonucleotides
containing 5' SmaI and 3' EcoRI restriction
sites. This allowed the products to be cloned in frame into similarly
digested pGex-2T bacterial expression vector (Pharmacia). The encoded
proteins were expressed in Escherichia coli at the C
terminus of glutathione S-transferase (GST) according to the manufacturer's instructions. Full-length human Grb2 and isolated N-terminal (residues 1 to 58) and C-terminal (residues 159 to 217) SH3
domains were also produced in this way using oligonucleotides containing a BamHI restriction site at the 5' end and an
EcoRI site at the 3' end. The fidelity of all cDNA produced
by PCR was verified by sequence analysis (MRC CSC core facility;
Imperial College School of Medicine). Proteins expressed by this method were purified to homogeneity using glutathione-Sepharose affinity chromatography (Pharmacia). They were then eluted from beads upon incubation with buffer containing excess glutathione (10 mM) that was
later removed by dialysis.
Immunoprecipitation and affinity purification.
Cultures
treated in the absence or presence of EGF (100 nM) at 37°C were lysed
at 4°C using the Triton X-100-based lysis buffer. Lysates were
clarified by centrifugation (13,000 × g, 20 min), and
the supernatants were transferred to a fresh tube. Immunoprecipitations were performed at 4°C over 4 h, and the immune complexes were collected on protein A-Sepharose (Pharmacia). Beads were briefly centrifuged and washed three times in lysis buffer prior to further analysis. Immobilized fusion proteins or GST alone were also assayed for their ability to affinity purify proteins from mammalian cell lysates. Recombinant protein was recovered on glutathione-Sepharose beads (4 h, 4°C).
Western blotting.
Immunoprecipitates were extracted in
sample buffer (200 mM Tris-HCl, 6% sodium dodecyl sulfate [SDS], 2 mM EDTA, 4% 2-mercaptoethanol, 10% glycerol, pH 6.8) and fractionated
by SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were
transferred to polyvinylidene difluoride (PVDF) membranes that were
blocked with 5% nonfat dried milk in phosphate-buffered saline (PBS)
containing 0.05% Tween 20, pH 7.2, and then were incubated for 2 to
4 h with antibody in PBS-Tween containing 3% nonfat milk.
Immunoreactive proteins were detected using either anti-mouse or
anti-rabbit coupled horseradish peroxidase (Amersham) and visualized by
ECL (Amersham).
Cell-free protein phosphorylation.
Immunoprecipitates
were washed twice with lysis buffer and again with in vitro kinase
buffer (20 mM HEPES [pH 7.5], 100 mM NaCl, 10 mM
MgCl2, and 15 mM MnCl2) at
4°C. Following the addition of 10 µM ATP, immunoprecipitates were
incubated in a total volume of 50 µl for 20 min at 30°C. Reactions
were terminated upon addition of excess kinase buffer at 4°C.
Assay of phosphoinositide kinase activity.
Lipid kinase
assays were performed in a total volume of 30 µl containing 20 mM
HEPES (pH 7.4), 100 mM NaCl, 0.1 mM EGTA, 0.1 mM EDTA, and 200 µg of
phosphatidylinositol/ml. After preincubating sonicated lipid with
sample for 10 min, reactions were initiated upon addition of divalent
cation (6 mM) and 100 µM ATP (0.2 µCi of
[
-32P]ATP). Assays were incubated at 30°C
for 20 min and then were terminated with acidified chloroform:methanol
(1:1 [vol/vol]). The extracted lipid products were fractionated by
thin-layer chromatography. Phosphoinositides were visualized by
autoradiography and were quantified by scanning densitometry. All
assays were linear with respect to time and enzyme addition.
Inhibition of SH3 domain-mediated binding to proline-rich
regions.
Peptides corresponding to each of three PI3K-C2
proline-rich motifs at residues 127 to 140 (KKLSPPPLPPRASI), 140 to 153 (IWDTPPLPPRKGSP), and 252 to 265 (SKTMPPQVPPRTYA) or a control peptide
representing residues 69 to 82 (NSLSPLEGPPNHST) were synthesized,
high-performance liquid chromatography purified, and lyophilized (Alta
Bioscience, Birmingham, United Kingdom). After reconstitution in PBS
and neutralization with NaOH (0.1 N), the concentration was determined
spectrophotometrically. Each peptide (25 µM) was added to an
EGFR-PI3K-C2
association assay.
 |
RESULTS |
The N terminus of PI3K-C2
but not PI3K-C2
affinity purifies
the activated EGFR.
Lysates prepared from A431 cells were treated
for 10 min in the presence or absence of EGF (100 nM). To these,
recombinant protein representing GST, GST-PI3K-C2
(2-345),
GST-PI3K-C2
(2-298), or GST-PI3K-C2
(1549-1686) (C2
domain) was added (10 µg) together with glutathione-Sepharose beads.
After 4 h at 4°C, the beads were isolated by centrifugation and
washed three times with lysis buffer. Associated proteins were
extracted with sample buffer. Once fractionated by SDS-PAGE and
transferred onto PVDF, proteins were Western blotted with
anti-phosphotyrosine or anti-EGFR antibody. A major band at
approximately 170 kDa representing phosphorylated EGFR (Fig.
1, upper panel) was isolated only with
PI3K-C2
(2-298) from EGF-stimulated lysates. Importantly, the
equivalent region of PI3K-C2
(2-345) was unable to bind EGFR in the
same manner. Two minor phosphotyrosine-containing proteins at
approximately 47 and 52 kDa were also isolated by the N-terminal
PI3K-C2
fusion protein. Western blotting with anti-EGFR antibody
confirmed that the major tyrosine phosphoprotein band represented EGFR
(Fig. 1, lower panel).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
The N terminus of PI3K-C2 but not PI3K-C2
interacts with the EGFR. A431 cells were incubated in the absence ( )
or presence (+) of EGF (100 nM) for 10 min. Cell lysates were prepared
and incubated with either GST, GST-PI3K-C2 (2-345),
GST-PI3K-C2 (2-298), or GST-PI3K-C2 (1549-1686) for 4 h at
4°C. Fusion protein was isolated using glutathione-Sepharose beads,
and associated proteins were fractionated by SDS-PAGE. Membranes were
Western blotted with antiphosphotyrosine antibody (upper panel) or
anti-EGFR antibody (lower panel). Arrows indicate the EGFR
(approximately 180 kDa) and associated phosphoproteins. PY,
phosphotyrosine.
|
|
Both Shc and Grb2 are present with activated EGFR following its
isolation by PI3K-C2
(2-298).
Lysates prepared from
EGF-stimulated A431 cells were incubated for 4 h with various
concentrations of recombinant PI3K-C2
(2-298) fusion protein as
previously described. The fusion and associated proteins were recovered
using glutathione-Sepharose beads and were Western blotted following
fractionation by SDS-PAGE. Figure 2,
upper panel, shows that the N-terminal fragment of PI3K-C2
affinity
purifies the activated EGFR in a dose-dependent manner. Again,
phosphoproteins at 47 and 52 kDa were clearly evident in these samples,
their appearance correlating with increased EGFR binding. The
association of the adaptor protein Shc with phosphorylated EGFR has
been well documented, and it exists as isoforms with a molecular mass
similar to that of the lower-molecular-mass phosphoproteins detected
with the antiphosphotyrosine antibody. The presence of p47 and p54 Shc
was confirmed using anti-Shc antibody (Fig. 2, middle panel).
Similarly, Western blotting also demonstrated the presence of Grb2 in
these samples (Fig. 2, lower panel).

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 2.
PI3K-C2 (2-298) affinity purifies EGFR, Shc, and Grb2
in a dose-dependent manner. Lysates from EGF-stimulated A431 cells were
incubated with various additions of recombinant GST-PI3K-C2 (2-298)
protein as shown. After 4 h at 4°C the fusion and associated
proteins were isolated by centrifugation and were washed. They were
then extracted, fractionated by SDS-PAGE, and Western blotted with
antiphosphotyrosine (upper panel), anti-Shc (middle panel), or
anti-Grb2 (lower panel). PY, phosphotyrosine.
|
|
Association of PI3K-C2
(2-298) with activated EGFR is
competitively inhibited by proline-rich peptides.
Since
PI3K-C2
(2-298) but not the equivalent region of PI3K-C2
was able
to affinity purify the activated EGFR, we examined the contribution of
the proline-rich motifs that characterize this N-terminal fragment.
Proline-rich regions with the consensus PXXP are established binding
sites for SH3 domain-containing molecules (20). Since
several signaling molecules that directly bind activated EGFR contain
SH3 domains, they could potentially serve as docking sites for
molecules with such proline-rich motifs. Lysates of A431 cells
stimulated with EGF were preincubated with synthetic peptides derived
from each of the three proline-rich regions in PI3K-C2
for 30 min at
4°C. Recombinant PI3K-C2
(2-298) was then added to these samples
for 4 h. Fusion protein was then isolated using
glutathione-Sepharose beads, washed, and fractionated by SDS-PAGE.
Samples were Western blotted to reveal the association of
phosphorylated EGFR. Figure 3 shows that
in the presence of peptide derived from each PI3K-C2
proline-rich
region, the interaction between PI3K-C2
(2-298) and the EGFR was
markedly attenuated (residues 127 to 140, 91%; 140 to 153, 92%; and
252 to 265, 81%). In contrast, a control sequence (residues 69 to 82)
exerted no inhibitory effect. When combinations of these peptides were
used, the isolation of the EGFR could be completely abolished.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
Polyproline-rich peptides competitively attenuate the
association of PI3K-C2 with the EGFR. Peptides (25 µM)
corresponding to each of the three PI3K-C2 polyproline-rich regions
at residues 127 to 140 (KKLSPPPLPPRASI), 140 to 153 (IWDTPPLPPRKGSP)
and 252 to 265 (SKTMPPQVPPRTYA) or control residues 69 to 82 (NSLSPLEGPPNHST) were added to lysates of EGF-stimulated A431
cells. Samples were incubated at 4°C, and recombinant
PI3K-C2 (2-298) (5 µg) was added 30 min later together with
glutathione-Sepharose beads. After 4 h at 4°C, fusion protein
was isolated by centrifugation, fractionated by SDS-PAGE, and Western
blotted with antiphosphotyrosine (upper panel) or anti-PI3KC2
antibody (lower panel). PY, phosphotyrosine.
|
|
Affinity purification of the EGFR by N-terminal fragments of
PI3K-C2
systematically lacking proline-rich motifs.
To further
demonstrate the role of the proline-rich motifs in the association of
PI3K-C2
with the EGFR, we used PCR to produce cDNA encoding a series
of N-terminal fragments (residues 2 to 130, 2 to 143, 2 to 157, and 2 to 255) and compared the degree of receptor binding to the 2-298 construct. Fragments were truncated around each proline-rich region
such that 2-130 has no proline-rich motifs, 2-143 has one, 2-157 and
2-255 have two, and 2-298 has three. Proteins were expressed as GST
fusions and incubated in lysates of EGF-stimulated cells. Figure
4 (upper panel) shows that their ability
to isolate the phosphorylated EGFR was dependent upon the number of
proline-rich motifs each fragment contained. A minimum of two
proline-rich motifs were required for receptor association, since the
protein 2-143, containing the first proline-rich region alone, was
unable to purify the EGFR. Interestingly, proteins representing
residues 2 to 157 and 2 to 252 of PI3K-C2
both contained two
proline-rich regions yet the latter bound EGFR with higher avidity. The
reason for this discrepancy is unclear, since both proteins were able
to bind endogenous Grb2 similarly (Fig. 4, lower panel).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 4.
N-terminal fragments of PI3K-C2 establish that two
proline-rich motifs are required for association with EGFR. A series of
GST fusion proteins representing residues 2 to 130, 2 to 143, 2 to 157, 2 to 255, and 2 to 298 were incubated for 4 h at 4°C with
lysates of A431 cells that had been treated in the absence ( ) or
presence (+) of EGF (100 nM) for 10 min. For control, EGFR was also
immunoprecipitated from these lysates (Ab1; Oncogene Science). Each
fusion and associated protein was isolated using glutathione-Sepharose
beads, washed, fractionated by SDS-PAGE, and Western blotted with
antiphosphotyrosine antibody to visualize the activated EGFR (upper
panel) and anti-Grb2 antibody (lower panel). PY, phosphotyrosine.
|
|
PI3K-C2
directly associates with Grb2.
Although the results
presented above demonstrated that the interaction between the N
terminus of PI3K-C2
and EGFR is dependent upon proline-rich regions,
they did not identify the intermediary protein responsible. A
consistent finding in our Western blots is the presence of the SH2/SH3
domain-containing adaptor Grb2 in these PI3K-C2
complexes (Fig. 2
and 4). Although this might have been a consequence of isolating the
activated EGFR to which Grb2 is recruited, we examined whether EE
epitope-tagged PI3K-C2
directly bound recombinant Grb2 in vitro.
PI3K-C2
expressed in HEK293 cells was isolated with anti-EE tag
antibody on protein A-Sepharose and was eluted from the beads using an
excess of a peptide derived from the epitope tag. Aliquots of the PI3K
enzyme (1 µg) were added to lysis buffer containing recombinant Grb2 GST (1 µg). Following a 4-h incubation at 4°C, either PI3K-C2
was isolated using anti-EE tag antibody and protein A-Sepharose or
GST-Grb2 was isolated with glutathione-Sepharose beads. Figure 5 demonstrates that isolation of both
Grb2-GST and epitope-tagged PI3K-C2
reciprocally copurified the
other protein.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 5.
Recombinant Grb2 and PI3K-C2 associate in vitro.
Grb2-GST fusion protein (1 µg) was added to Triton lysis buffer (500 µl) in the absence or presence of EE epitope-tagged PI3K-C2 (1 µg) and either glutathione-Sepharose beads or anti-EE tag antibody
(Ab) and protein A-Sepharose. After incubation at 4°C for 4 h,
beads were isolated by centrifugation and washed. Associated proteins
were extracted, fractionated by SDS-PAGE, and Western blotted with
either anti-PI3K-C2 antibody (upper panel) or anti-Grb2 antibody
(lower panel) and visualized with ECL.
|
|
Both the N-terminal and C-terminal Grb2 SH3 domains bind PI3K-C2
proline-rich regions.
cDNA encoding both the N-terminal (residues
1 to 58) and C-terminal (residues 159 to 217) SH3 domains of Grb2 were
amplified by PCR, subcloned into pGex2T vector, and expressed as GST
fusion proteins. Figure 6A shows aliquots
of each soluble fusion protein extracted, fractionated by SDS-PAGE, and
visualized by Coomassie blue staining. Soluble PI3K-C2
N-terminal
fragments were produced upon their cleavage from GST with thrombin.
Aliquots were fractionated by SDS-PAGE and Western blotted with
anti-PI3K-C2
antisera to demonstrate antibody cross-reaction (Fig.
6B). Each SH3 domain fusion, full-length Grb2, or GST alone was
incubated (2 h, 4°C) with the N-terminal PI3K-C2
fragments.
Following recovery with glutathione-Sepharose, the GST fusions together
with their associated proteins were fractionated by SDS-PAGE and
Western blotted with anti-PI3K-C2
antibody. The middle and lower
panels of Fig. 6 show that no PI3K-C2
N-terminal fragments bound
GST. Fragments containing either two proline-rich regions (residues 2 to 157 and 2 to 255) or three proline-rich regions (residues 2 to 298) were affinity purified with full-length Grb2 and each SH3 domain. The
fragment lacking a proline-rich region (residues 2 to 130) or
containing only one (residues 2 to 143) did not bind Grb2 or either SH3
domain.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 6.
Both N-terminal and C-terminal Grb2 SH3 domains (N-SH3
and C-SH3, respectively) bind PI3K-C2 . The N-terminal and C-terminal
SH3 domains of Grb2 together with full-length Grb2 adaptor were
expressed as GST fusion proteins and visualized by Coomassie blue
staining following SDS-PAGE (panel A). The N-terminal PI3K-C2
fragments 2-130, 2-143, 2-157, 2-255, and 2-298 were expressed as GST
fusion proteins, purified using glutathione-Sepharose beads, and
cleaved with 5 µg of thrombin/ml (2 h, 21°C). Each protein was
fractionated by SDS-PAGE and Western blotted with anti-PI3K-C2
antisera to confirm cross-reaction (panel B). Aliquots of each
PI3K-C2 N-terminal fragment were incubated (2 h, 4°C) with either
GST, full-length Grb2, or N-terminal or C-terminal Grb2 SH3 domain.
Each GST fusion was isolated with glutathione-Sepharose beads, washed,
and fractionated by SDS-PAGE. The N-terminal fragments of PI3K-C2
were visualized by Western blotting with anti-PI3K-C2 antibody.
|
|
Grb2 association with PI3K-C2
in intact cells.
Confluent
and quiescent cultures of human breast cancer cell lines (HMT3551,
T47D, and SKBr3) and a human renal tubular epithelial cell line (HKC-8)
were stimulated with EGF (100 nM) for 10 min. Lysates were prepared and
incubated with anti-Grb2 antibody (Santa Cruz) and protein A-Sepharose
beads for 4 h at 4°C. After isolation and washing, the resultant
immune complexes were extracted, fractionated by SDS-PAGE, and Western
blotted with antisera to either PI3K-C2
(Fig.
7, upper panels), SOS1/2 (Santa Cruz)
(middle panels), or anti-EGFR (Santa Cruz) (lower panels). In each cell
type, both PI3K-C2
and SOS were constitutively associated with Grb2.
Following EGF stimulation, binding of Grb2 to EGFR was observed and
PI3K-C2
exhibited a slight but consistent retardation of its
electrophoretic mobility. This effect was more evident with SOS.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 7.
Isolation of PI3K-C2 , SOS, and EGFR in anti-Grb2
immunoprecipitates (ippt). Confluent and quiescent cultures of
human renal epithelial cells (HKC-8) and breast cancer cells (HTM3551,
T47D, and SKBr3) were incubated with (+) or without ( ) EGF (100 nM)
for 10 min. Lysates were prepared to which anti-Grb2 antibody (Santa
Cruz C-23) was added for 4 h at 4°C. Immune complexes were
isolated following addition of protein A-Sepharose and centrifugation.
Proteins were extracted, fractionated by SDS-PAGE, and Western blotted
with antisera to PI3K-C2 (upper panels), SOS 1/2 (D21; Santa Cruz)
(middle panels), and EGFR (1005; Santa Cruz) (lower panels).
|
|
Cultures of a squamous cell carcinoma cell line (A431), a prostate
cancer cell line (LNCaP), and a human embryonic kidney cell line
(HEK293) transfected with PI3K-C2
were also examined. Following
incubation with EGF, lysates were prepared and similarly immunoprecipitated with anti-Grb2 antibody. Immune complexes were then
isolated and aliquots were either fractionated by SDS-PAGE and Western
blotted with anti-PI3K-C2
antisera (Fig.
8, upper panel) or used for a
phosphoinositide kinase assay using PtdIns as the substrate and
Ca2+ as the divalent cation (lower panel). In
agreement with data presented in Fig. 7, PI3K-C2
was constitutively
associated with Grb2. The lower panel of Fig. 8 shows that the lipid
kinase activity associated with anti-p85
immunoprecipitates from
A431 cell lysates was abolished when Ca2+ instead
of Mg2+ was used as the divalent cation in the
kinase reaction. The catalytic activity of recombinant PI3K-C2
and
anti-Grb2 immunoprecipitates was evaluated in the presence of
Ca2+. Results obtained with each cell line
support the constitutive association of PI3K-C2
with Grb2 identified
by Western blotting. Intriguingly, the effect of EGF stimulation
differed depending on the cell type examined. In A431 and HEK293 cells,
EGF stimulation slightly decreased the activity while in LNCaP cells
catalytic activity in the Grb2 immunoprecipitates was elevated.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 8.
Grb2 associates with PI3K-C2 in vivo. Cultures of
confluent and quiescent A431, LNCaP, and HEK293 cells that overexpress
epitope-tagged PI3K-C2 were incubated in the absence ( ) or
presence (+) of EGF (100 nM) for 10 min. Lysates were prepared and
immunoprecipitated (ippt) with anti-Grb2 antisera for 4 h at
4°C. Immune complexes were isolated with protein A-Sepharose. These
were either extracted, fractionated by SDS-PAGE, and Western blotted
with anti-PI3K-C2 antisera (upper panels) or used for lipid kinase
assay with PtdIns as the substrate and Ca2+ as the divalent
cation (lower panels). The activity of recombinant PI3K-C2 is shown
as a control, as is the class IA PI3K activity immunoprecipitated from
A431 cell lysates using anti-p85 antibody.
|
|
Association with Grb2 increases the specific activity of the
PI3K-C2
enzyme in vitro.
To assess the functional significance
of the observed interaction between Grb2 and PI3K-C2
, we examined
its effect upon the catalytic activity of the PI3K enzyme. Aliquots of
recombinant EE-tagged PI3K-C2
(100 ng) were incubated in PI3K assay
buffer in the presence or absence of GST-Grb2 (100 ng) for 2 h at
4°C. This mixture was added to EGFR immunoprecipitated from cultures of quiescent A431 cells and subsequently autophosphorylated in vitro
upon addition of ATP. Controls included GST and mock EGFR immunoprecipitates. Incubation was continued for a further 1 h. At
the end of this time, PtdIns was added and a lipid kinase assay was performed in the presence of
[
-32P]ATP. Figure
9 shows that association of PI3K-C2
with Grb2 produced a greater than sevenfold increase in the catalytic
activity of this PI3K enzyme. This stimulation did not further increase
in the presence of nonphosphorylated receptor, although phosphorylated EGFR attenuated this effect (3.3-fold potentiation). Unexpectedly, the
presence of EGFR immunoprecipitated from quiescent cells alone also
markedly stimulated PI3K-C2
enzyme activity (5.8-fold). Using
phosphorylated receptor, this effect was also less marked (3.5-fold).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 9.
Grb2 increases the catalytic activity of PI3K-C2 .
Aliquots of recombinant EE-tagged PI3K-C2 (100 ng) were incubated in
PI3K assay buffer for 2 h at 4°C with either Grb2-GST fusion
protein (100 ng) or GST. After this time, immobilized EGFR previously
immunoprecipitated (Ab-1; Oncogene Science) from lysates of quiescent
A431 cells and autophosphorylated in vitro or mock control was added.
Incubation was continued for a further 1 h. Following addition of
kinase buffer, phosphatidylinositol (200 µg/ml) and
[ -32P]ATP, samples (50 µl) were incubated at room
temperature for 20 min. Radiolabeled phosphoinositides were extracted
and aliquots were fractionated by thin-layer chromatography and
visualized by autoradiography. Representative data are shown in the
upper panel. Quantification of PtdIns3P was undertaken by scanning
densitometry. In the lower panel, data are displayed as means ± standard errors of the means (n = 6). Under the
conditions used, all reactions displayed linear kinetics.
|
|
Formation of a EGFR-Grb2-PI3K-C2
complex in vitro.
Finally, we examined whether a complex containing EGFR, Grb2, and
PI3K-C2
could be formed in vitro. As described above, recombinant EE-tagged PI3K-C2
was incubated with GST-Grb2 for 2 h at 4°C. EGFR was immunoprecipitated from quiescent A431 cultures and
autophosphorylated in vitro. Aliquots of phosphorylated and
nonphosphorylated receptors were then added and the incubation was
continued for a further 1 h. The EGFR and associated proteins were
isolated by centrifugation, washed with lysis buffer, and extracted.
After fractionation by SDS-PAGE, proteins were Western blotted to
determine the presence of EGFR, phosphorylated EGFR, Grb2, and
PI3K-C2
. Figure 10 shows that
recombinant GST Grb2 associated only with immunoprecipitated EGFR that
was autophosphorylated in vitro (Phospho-EGFR). Critically, PI3K-C2
only associated with phosphorylated EGFR in the presence of GST-Grb2.
No significant association of this PI3K to nonphosphorylated EGFR was
evident under these conditions.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 10.
Formation of the EGFR-Grb2-PI3K-C2 complex in
vitro. Recombinant EE-tagged PI3K-C2 (100 ng) was incubated in lysis
buffer for 2 h at 4°C in the absence or presence of Grb2-GST
fusion protein (100 ng) or GST. Immobilized EGFR, isolated by
immunoprecipitation (Ab1; Oncogene Science) from lysates of confluent
and quiescent cultures of A431 cells, was phosphorylated for 30 min at
30°C in protein kinase buffer upon addition of ATP. Either
phosphorylated EGFR, nonphosphorylated EGFR, or mock immunoprecipitate
was added to the Grb2-PI3K-C2 sample, and the incubation was
continued for a further 1 h. Beads containing immobilized receptor
and associated proteins were isolated by centrifugation, washed,
fractionated by SDS-PAGE, and Western blotted with either anti-EGFR
antibody, antiphosphotyrosine, anti-Grb2, or anti-PI3K-C2 antibody.
PY, phosphotyrosine.
|
|
 |
DISCUSSION |
In this study we sought to delineate the binding site on
PI3K-C2
involved in recruiting this enzyme to the activated EGFR (2). Although the N terminus of this PI3K enzyme mediates
this association, it lacks any domain that can directly bind the
receptor. We have produced three independent pieces of data to
demonstrate the involvement of its proline-rich motifs in this effect.
Figure 1 shows that the N-terminal fragment of PI3K-C2
but not
PI3K-C2
affinity purified activated EGFR from cell lysates. The N
terminus of PI3K-C2
(13) and PI3K-C2
both contain
motifs that form the P-X-X-P consensus that favors interaction with SH3
domains (20, 39). Secondly, peptides based on each
proline-rich region were able to competitively attenuate the
interaction between PI3K-C2
and EGFR (Fig. 3). In contrast, a
control peptide based on an adjacent sequence had no effect. This
approach was successfully used in many previous studies to define the
sites of protein-protein interaction (3, 4, 28). Finally,
fragments of the PI3K-C2
N terminus expressed as GST fusions
demonstrated that either two proline-rich motifs are required for EGFR
binding or the proline-rich motif at residues 144 to 149 is critical
for this interaction (Fig. 4). However, data presented in Fig. 3 show
that peptides derived from all three proline-rich motifs are equally
able to displace EGFR binding, making this latter possibility less likely.
Given the importance of the proline-rich motifs in PI3K-C2
-EGFR
association we sought to identify a molecule that could mediate this
interaction. From our earliest experiments we recognized that both the
Shc and Grb2 adaptor proteins were isolated by the PI3K-C2
N
terminus together with EGFR from cell lysates (Fig. 2 and 4). Of these
two molecules, only Grb2 contains an SH3 domain capable of binding
proline-rich motifs. The Grb2 adaptor (also termed Ash) is the human
homologue of the Caenorhabditis elegans protein Sem-5 and
consists of a single SH2 domain flanked by two SH3 domains. Recruitment
of Grb2 to activated EGFR is mediated by the SH2 domain and can occur
either directly or via phosphorylated Shc (4, 7). The
degree to which Grb2 associates directly with the EGFR or indirectly
via Shc appears to be dependent upon the cell type examined, although
direct interaction with the receptor is often favored
(36). Each SH3 domain preferentially binds proteins
containing proline-rich motifs that adopt a left-handed polyproline
type II helix with the minimal consensus sequence P-X-X-P
(33). However, structural and binding studies have since refined this consensus to P-X-X-P-X-R (6). Each of the
three proline-rich motifs present within the N terminus of PI3K-C2
obeys this consensus. The best-characterized binding partner of the
Grb2 SH3 domain is the nucleotide exchange factor SOS that in turn acts
as a positive regulator of p21ras (6, 7). Many
studies have demonstrated that the Grb2 SH3 domains bind effectors in
addition to SOS. These include adaptor proteins (Gab 1 and 2, Cbl, and
Slp-76) (21, 26, 41, 48), phosphotyrosine phosphatases
(SHP-2, PEST) (10, 47), serine/threonine kinases (MEKK1)
(34), several proteins implicated in cytoskeletal reorganization (dynamin, N-Wasp) (20, 27), receptors
(CD28) (29), and other guanine nucleotide exchange factors
for ras-related proteins (Vav, C3G) (38, 43).
We show that recombinant Grb2 directly binds full-length PI3K-C2
in
vitro (Fig. 5). Data presented in Fig. 6 demonstrate that both the
N-terminal and C-terminal Grb2 SH3 domain can bind PI3K-C2
although,
in agreement with Fig. 4, two proline-rich regions were required. It
remains unclear why Grb2 binds PI3K-C2
(2-157) and PI3K-C2
(2-255)
with equal affinity yet EGFR binding was significantly greater using
fragment 2-255. It suggests that the association of Grb2 and PI3K-C2
occurs independently of the EGFR and that this complex forms first
within the cell before translocating to the activated receptor.
Although it is possible that residues 158 to 255 of PI3K-C2
contain
a motif that stabilizes the PI3K-C2
-EGFR interaction, we have
expressed this region as a GST fusion protein and found that it does
not bind phosphorylated EGFR independently (data not shown).
Constitutive interaction between endogenous Grb2 and PI3K-C2
was
also demonstrated when the PI3K enzyme was identified in
immunoprecipitates of Grb2 from numerous cell lysates (Fig. 7 and 8),
including one cell line (HEK293) that was transfected with recombinant
PI3K-C2
. Figure 7 shows that while EGF stimulation translocates Grb2
to the activated EGFR, it does not alter the stoichiometry of
PI3K-C2
or SOS binding, nor does it display a dramatic effect on the
catalytic activity of the PI3K enzyme in situ (Fig. 8). In contrast,
data presented in Fig. 9 show that the interaction of Grb2 and
immunoprecipitated EGFR dramatically increased (sevenfold) PI3K-C2
lipid kinase activity. The effect of EGFR was unexpected, given that
the receptor does not directly bind PI3K-C2
. However, since the EGFR
was isolated by immunoprecipitation from cell lysates, these
preparations might contain associated molecules that exert this effect.
The increase in specific activity conferred by EGFR and Grb2 was
neither synergistic nor additive, suggesting that they share the same
mechanism of activation. It is also unclear why addition of
phosphorylated EGFR produced a lesser activation than nonphosphorylated
receptor. However, this finding was consistent with data presented in
Fig. 8 for A431 and HEK293 cells.
Further studies are required to determine if Grb2 is the only adaptor
able to mediate association of PI3K-C2
to EGFR. Other SH3
domain-containing proteins recruited to the activated EGFR may also
play a role. Potential candidates include Nck (17), phospholipase C
, ras GTPase-activating protein GAP1(m), and vav-2 (31). Since our data suggest the need for at least two
proline-rich motifs (Fig. 4 and 6), it seems unlikely that an adaptor
containing a single SH3 domain could mediate the interaction between
EGFR and PI3K-C2
without the formation of a higher-order complex. Indeed, despite the presence of an SH3 domain, p85 adaptor protein cannot bind PI3K-C2
(1). Our previous failure to
identify a protein that coimmunoprecipitates with either PI3K-C2
or
PI3K-C2
in high stoichiometry contrasts with the association of
class IA catalytic subunits and the p85 adaptor (2).
However, those experiments were performed using antisera directed
against the N-terminal sequence of the class II PI3K enzymes.
Consequently, it is possible that proteins associated with PI3K-C2
could block its antigenic epitopes or that an excess of antibody
competes with binding partners for similar or overlapping epitopes,
resulting in their dissociation.
Important questions remain regarding the significance of class II PI3K
recruitment for biological responses downstream of EGFR. One
possibility is their involvement in the regulation of receptor
internalization. Although the mechanism of EGFR internalization has
attracted particular attention, little is understood about which
signals trigger their recruitment into clathrin-coated vesicles. Pharmacological inhibition using wortmannin clearly demonstrates a role
for PI3K activity (22, 23), and we have recently confirmed the presence of PI3K-C2
in clathrin-coated vesicle preparations and
its ability to regulate clathrin-mediated endocytosis and sorting in
the trans Golgi network (12, 16). Ligand
binding triggers recruitment of EGFR to clathrin-coated pits and its
subsequent delivery to lysosomes for degradation. Experiments using
fluorescent GFP-tagged p85
and a chimeric EGFR-ErbB-3 receptor show
that despite recruitment of the class I PI3K adaptor and a clustering of staining into patches, there was no evidence of receptor
internalization or its association with clathrin-containing
endosomes following EGF stimulation (19).
Interestingly, Grb2 is also required for efficient receptor
endocytosis (46). Characterization of the FYVE domain
(8, 18, 32) has illustrated how PI3K-dependent vesicle
trafficking is regulated by generation of PtdIns3P rather than by
PtdIns(3,4)P2 or
PtdIns(3,4,5)P3, which are considered to be the
principle products of class IA PI3K enzyme activity. Although
production of PtdIns3P has been largely attributed to the class III
PI3K vps34p homologue, the class II PI3K enzymes may also contribute to
its generation in vivo and therefore play a regulatory role in these events.
Since both PI3K-C2
and PI3K-C2
share an extensive and overlapping
tissue distribution and play a role downstream of several receptors, it
is important to establish if they are regulated in a similar or
disparate manner. Although both class II PI3K isozymes lie downstream
of the activated EGFR, the results of this study demonstrate that
PI3K-C2
and not PI3K-C2
is recruited to the receptor by a
mechanism involving proline-rich regions and the Grb2 adaptor.
Consequently, this observation offers scope for the differential
regulation of PI3K-C2
and PI3K-C2
catalytic activity and thus the
development of compounds to selectively antagonize the action of each
class II PI3K isozyme.
We thank Tony Pawson for his generous provision of human Grb2
pcDNA3.0 cDNA. We are grateful to Charles Coombes, Imperial College
School of Medicine, for provision of the T47D, SKBr3, and HMT3522
breast cancer cell lines and to L. Racusen, The John Hopkins University
School of Medicine, Baltimore, Md., for the human renal tubular
epithelial cell line HKC-8.
| 1.
|
Arcaro, A.,
S. Volinia,
M. J. Zvelebil,
R. Stein,
S. J. Watton,
M. J. Layton,
I. Gout,
K. Ahmadi,
J. Downward, and M. D. Waterfield.
1998.
Human PI3-kinase C2 the role of calcium and the C2 domain in enzyme activity.
J. Biol. Chem.
273:33082-33091[Abstract/Free Full Text].
|
| 2.
|
Arcaro, A.,
M. J. Zvelebil,
C. Wallasch,
A. Ullrich,
M. D. Waterfield, and J. Domin.
2000.
Class II phosphoinositide 3-kinase are downstream targets of activated polypeptide growth factor receptors.
Mol. Cell. Biol.
20:3817-3830[Abstract/Free Full Text].
|
| 3.
|
Batzer, A. G.,
P. Blaikie,
K. Nelson,
J. Schlessinger, and B. Margolis.
1995.
The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.
Mol. Cell. Biol.
15:4403-4409[Abstract].
|
| 4.
|
Batzer, A. G.,
D. Rotin,
J. M. Urena,
E. Y. Skolnik, and J. Schlesinger.
1994.
Hierachy of binding sites for grb-2 and Shc on the epidermal growth factor receptor.
Mol. Cell. Biol.
14:5192-5201[Abstract/Free Full Text].
|
| 5.
|
Brown, R. A.,
J. Domin,
A. Arcaro,
M. D. Waterfield, and P. R. Shepherd.
1999.
Insulin activates the alpha isoform of class II phosphoinositide 3-kinase.
J. Biol. Chem.
274:14529-14532[Abstract/Free Full Text].
|
| 6.
|
Bunday, L.
1999.
Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins.
Biochim. Biophys. Acta
1422:187-204[Medline].
|
| 7.
|
Bunday, L., and J. Downward.
1993.
Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein and Sos nucleotide exchange factor.
Cell
73:611-620[CrossRef][Medline].
|
| 8.
|
Burd, C. G., and S. D. Emr.
1998.
Phosphatidylinositol (3)-phosphate signalling mediated by specific binding to RING FYVE domains.
Mol. Cell
2:157-162[CrossRef][Medline].
|
| 9.
|
Carter, A. N., and C. P. Downes.
1992.
Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells.
J. Biol. Chem.
267:14563-14567[Abstract/Free Full Text].
|
| 10.
|
Charest, A.,
J. Wagner,
M. Kwan, and M. Tremblay.
1997.
Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2.
Oncogene
14:1643-1651[CrossRef][Medline].
|
| 11.
|
Cohen, G. B.,
R. Ren, and D. Baltimore.
1995.
Modular binding domains in signal transduction proteins.
Cell
80:237-248[CrossRef][Medline].
|
| 12.
|
Domin, J.,
I. Gaidarov,
M. Smith,
J. Keen, and M. Waterfield.
2000.
The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles.
J. Biol. Chem.
275:11943-11950[Abstract/Free Full Text].
|
| 13.
|
Domin, J.,
F. Pages,
S. Volinia,
S. E. Rittenhouse,
M. J. Zvelebil,
R. C. Stein, and M. D. Waterfield.
1997.
Cloning of a human phosphatidylinositol 3-kinase with a C2 domain which displays reduced sensitivity to the inhibitor wortmannin.
Biochem. J.
326:139-147.
|
| 14.
|
Domin, J., and M. D. Waterfield.
1997.
Using structure to define the function of phosphoinositide 3-kinase family members.
FEBS Lett.
410:91-95[CrossRef][Medline].
|
| 15.
|
Fruman, D. A.,
R. E. Meyers, and L. C. Cantley.
1998.
Phosphoinositide kinases.
Annu. Rev. Biochem.
67:481-507[CrossRef][Medline].
|
| 16.
|
Gaidarov, I.,
M. E. Smith,
J. Domin, and J. H. Keen.
2001.
The class II phosphoinositide 3-kinase C2 alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking.
Mol. Cell
7:443-449[CrossRef][Medline].
|
| 17.
|
Galisteo, M.,
J. Chernoff,
Y. Su,
E. Skolnik, and J. Schlessinger.
1996.
The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1.
J. Biol. Chem.
271:20997-21000[Abstract/Free Full Text].
|
| 18.
|
Gaullier, J. M.,
A. Simonsen,
A. D'Arrigo,
B. Bremnes,
H. Stenmark, and R. Aasland.
1998.
FYVE fingers bind PtdIns(3)P.
Nature
394:432-433[CrossRef][Medline].
|
| 19.
|
Gillham, H.,
M. C. H. M. Golding,
R. Pepperkok, and W. J. Gullick.
1999.
Intracellular movement of green fluorescent protein-tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling.
J. Cell Biol.
146:869-880[Abstract/Free Full Text].
|
| 20.
|
Gout, I.,
R. Dhand,
I. D. Hiles,
M. J. Fry,
G. Panayotou,
P. Das,
O. Truong,
N. F. Totty,
J. Hsuan,
G. W. Booker,
I. D. Campbell, and M. D. Waterfield.
1993.
The GTPase dynamin binds to and is activated by a subset of SH3 domains.
Cell
75:25-36[CrossRef][Medline].
|
| 21.
|
Jackman, J.,
D. Motto,
Q. Sun,
M. Tanemoto,
C. Turck,
G. Peltz,
G. Koretzky, and P. Findell.
1995.
Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells.
J. Biol. Chem.
270:7029-7032[Abstract/Free Full Text].
|
| 22.
|
Joly, M.,
A. Kazlauskas, and S. Corvera.
1995.
Phosphatidylinositol 3-kinase activity is required at a postendocytic step in platelet-derived growth factor receptor trafficking.
J. Biol. Chem.
270:13225-13230[Abstract/Free Full Text].
|
| 23.
|
Joly, M.,
A. Kazlauskas,
F. S. Fay, and S. Corvera.
1994.
Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites.
Science
263:684-687[Abstract/Free Full Text].
|
| 24.
|
Leevers, S.,
B. Vanhaesebroeck, and M. Waterfield.
1999.
Signalling through phosphoinositide 3-kinases: the lipids take center stage.
Curr. Opin. Cell Biol.
11:219-225[CrossRef][Medline].
|
| 25.
|
Lowenstein, E. J.,
R. J. Daly,
A. G. Batzer,
W. Li,
B. Margolis,
R. Lammers,
A. Ullrich,
E. Y. Skolnik,
D. Bar-Sagi, and J. Schlesinger.
1992.
The SH2 and SH3 domain containing protein Grb2 links receptor tyrosine kinases to ras signaling.
Cell
70:431-442[CrossRef][Medline].
|
| 26.
|
Meisner, H.,
B. Conway,
D. Hartley, and M. Czech.
1995.
Interactions of Cbl with Grb2 and phosphatidylinositol 3' kinase in activated Jurkat cells.
Mol. Cell. Biol.
15:3571-3578[Abstract].
|
| 27.
|
Miki, H.,
K. Miura, and T. Takenawa.
1996.
N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases.
EMBO J.
15:5326-5335[Medline].
|
| 28.
|
Okabayashi, Y.,
Y. Kido,
T. Okutani,
Y. Sugimoto,
K. Sakaguchi, and M. Kasuga.
1994.
Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells.
J. Biol. Chem.
269:18674-18678[Abstract/Free Full Text].
|
| 29.
|
Okkenhaug, K., and R. Rottapel.
1998.
Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction.
J. Biol. Chem.
273:21194-21202[Abstract/Free Full Text].
|
| 30.
|
Olayioye, M.,
R. Neve,
H. Lane, and N. E. Hynes.
2000.
The ErbB signaling network: receptor heterodimerization in development and cancer.
EMBO J.
19:3159-3167[CrossRef][Medline].
|
| 31.
|
Pandey, A.,
A. Podtelejnikov,
B. Blagoev,
X. Bustelo,
M. Mann, and H. Lodish.
2000.
Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors.
Proc. Natl. Acad. Sci. USA
97:179-184[Abstract/Free Full Text].
|
| 32.
|
Patki, V.,
D. C. Lawe,
S. Corvera,
J. V. Virbasius, and A. Chawla.
1998.
A functional PtdIns(3)P-binding motif.
Nature
394:433-434[CrossRef][Medline].
|
| 33.
|
Pawson, T.
1995.
Protein modules and signalling networks.
Nature
373:573-580[CrossRef][Medline].
|
| 34.
|
Pomerance, M.,
M. Multon,
F. Parker,
C. Venot,
J. Blondeau,
B. Tocque, and F. Schweighoffer.
1998.
Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor.
J. Biol. Chem.
273:24301-24304[Abstract/Free Full Text].
|
| 35.
|
Prigent, S. A., and W. J. Gullick.
1994.
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.
EMBO J.
13:2831-2841[Medline].
|
| 36.
|
Prigent, S.,
M. Nagane,
H. Lin,
I. Huvar,
G. Boss,
J. Feramisco,
W. Cavenee, and H. Huang.
1996.
Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway.
J. Biol. Chem.
271:25639-25645[Abstract/Free Full Text].
|
| 37.
|
Raffioni, S., and R. A. Bradshaw.
1992.
Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor and nerve growth factor in PC12 phaeochromocytoma cells.
Proc. Natl. Acad. Sci. USA
89:9121-9125[Abstract/Free Full Text].
|
| 38.
|
Ramos-Morales, F.,
F. Romero,
F. Schweighoffer,
G. Bismuth,
J. Camonis,
M. Tortolero, and S. Fischer.
1995.
The proline-rich region of Vav binds to Grb2 and Grb3-3.
Oncogene
11:1665-1669[Medline].
|
| 39.
|
Ren, R.,
B. Mayer,
P. Cicchetti, and D. Baltimore.
1993.
Identification of a ten-amino acid proline-rich SH3 binding site.
Science
259:1157-1161[Abstract/Free Full Text].
|
| 40.
|
Riese, D. J., II, and D. F. Stern.
1998.
Specificity within the EGF family/ErbB receptor family signalling network.
BioEssays
20:41-48[CrossRef][Medline].
|
| 41.
|
Rodrigues, G. A.,
M. Falasca,
Z. Zhang,
S. H. Ong, and J. Schlessinger.
2000.
A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.
Mol. Cell. Biol.
20:1448-1459[Abstract/Free Full Text].
|
| 42.
|
Rozakis-Adcock, M.,
R. Fernley,
J. Wade,
T. Pawson, and D. Bowtell.
1993.
The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the ras activator mSos1.
Nature
363:83-85[CrossRef][Medline].
|
| 43.
|
Tanaka, S.,
T. Morishita,
Y. Hashimoto,
S. Hattori,
S. Nakamura,
M. Shibuya,
K. Matuoka,
T. Takenawa,
T. Kurata,
K. Nagashima, et al.
1994.
C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins.
Proc. Natl. Acad. Sci. USA
91:3443-3447[Abstract/Free Full Text].
|
| 44.
|
Turner, S. J.,
J. Domin,
M. D. Waterfield,
S. G. Ward, and J. Westwick.
1998.
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2 .
J. Biol. Chem.
273:25987-25995[Abstract/Free Full Text].
|
| 45.
|
Volinia, S.,
R. Dhand,
B. Vanhaesebroeck,
L. K. MacDougall,
R. Stein,
M. J. Zvelebil,
J. Domin,
C. Panaretou, and M. D. Waterfield.
1995.
A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system.
EMBO J.
14:3339-3348[Medline].
|
| 46.
|
Wang, Z., and M. Moran.
1996.
Requirement for the adapter protein GRB2 in EGF receptor endocytosis.
Science
272:1935-1939[Abstract].
|
| 47.
|
Wong, L., and G. R. Johnson.
1996.
Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2.
J. Biol. Chem.
271:20981-20984[Abstract/Free Full Text].
|
| 48.
|
Yart, A.,
M. Laffargue,
P. Mayeux,
S. Chretien,
C. Peres,
N. Tonks,
S. Roche,
B. Payrastre,
H. Chap, and P. Raynal.
2001.
A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
J. Biol. Chem.
276:8856-8864[Abstract/Free Full Text].
|
| 49.
|
Zhang, J.,
H. Banfic,
F. Straforini,
L. Tosi,
S. Volinia, and S. Rittenhouse.
1998.
A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate.
J. Biol. Chem.
273:14081-14084[Abstract/Free Full Text].
|